{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:11:49Z","timestamp":1791101509882,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.maturitas.2009.01.001","type":"journal-article","created":{"date-parts":[[2009,2,4]],"date-time":"2009-02-04T12:12:29Z","timestamp":1233749549000},"page":"270-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Diverse molecular pathways in ovarian cancer and their clinical significance"],"prefix":"10.1016","volume":"62","author":[{"given":"Carmela","family":"Ricciardelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin K.","family":"Oehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2009.01.001_bib1","series-title":"WHO world cancer report","year":"2003"},{"key":"10.1016\/j.maturitas.2009.01.001_bib2","first-page":"71","article-title":"Cancer statistics","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.maturitas.2009.01.001_bib3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.humpath.2006.10.007","article-title":"Alternate molecular genetic pathways in ovarian carcinomas of common histological types","volume":"38","author":"Willner","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ajog.2008.01.005","article-title":"Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis","volume":"198","author":"Kurman","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib5","first-page":"161","article-title":"Histologic subtypes of ovarian carcinoma: an overview","volume":"27","author":"Soslow","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/cr.2008.52","article-title":"Genomic analysis of epithelial ovarian cancer","volume":"18","author":"Farley","year":"2008","journal-title":"Cell Res"},{"key":"10.1016\/j.maturitas.2009.01.001_bib7","first-page":"151","article-title":"Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications","volume":"27","author":"Kurman","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1155\/2007\/474320","article-title":"Etiology and pathogenesis of epithelial ovarian cancer","volume":"23","author":"Mok","year":"2007","journal-title":"Dis Markers"},{"key":"10.1016\/j.maturitas.2009.01.001_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.2006.07.9970","article-title":"Early events in the pathogenesis of epithelial ovarian cancer","volume":"26","author":"Landen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib10","first-page":"5895","article-title":"Genetic analysis of early-versus late-stage ovarian tumors","volume":"61","author":"Shridhar","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.maturitas.2009.01.001_bib11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2009.01.001_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GCO.0b013e328011a21f","article-title":"The distal fallopian tube: a new model for pelvic serous carcinogenesis","volume":"19","author":"Crum","year":"2007","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib15","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.fertnstert.2008.08.007","article-title":"The relationship of endometriosis and ovarian malignancy: a review","volume":"90","author":"Nezhat","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2009.01.001_bib16","first-page":"7052","article-title":"Loss of heterozygosity on 10q23 3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary","volume":"60","author":"Sato","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.maturitas.2009.01.001_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/jcb.240590927","article-title":"The epidemiology of ovarian cancer","volume":"23","author":"Tortolero-Luna","year":"1995","journal-title":"J Cell Biochem Suppl"},{"key":"10.1016\/j.maturitas.2009.01.001_bib18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jnci\/84.8.592","article-title":"Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer","volume":"84","author":"Godwin","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2009.01.001_bib19","first-page":"2778","article-title":"Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity","volume":"54","author":"Testa","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.maturitas.2009.01.001_bib20","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/jnci\/90.23.1774","article-title":"Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone","volume":"90","author":"Risch","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2009.01.001_bib21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/0029-7844(96)00226-8","article-title":"Epithelial ovarian cancer risk among women with polycystic ovary syndrome","volume":"88","author":"Schildkraut","year":"1996","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0010-7824(96)00006-6","article-title":"Changes in androgens during treatment with four low-dose contraceptives","volume":"53","author":"Coenen","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2009.01.001_bib23","first-page":"157","article-title":"Androgens and ovarian cancers","volume":"25","author":"Wang","year":"2004","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib24","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/humrep\/dei462","article-title":"Endometriosis and the risk of cancer with special emphasis on ovarian cancer","volume":"21","author":"Melin","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.maturitas.2009.01.001_bib25","first-page":"667","article-title":"Pelvic inflammatory disease and risk of ovarian cancer","volume":"5","author":"Parazzini","year":"1996","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.maturitas.2009.01.001_bib26","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/jnci\/91.17.1459","article-title":"Possible role of ovarian epithelial inflammation in ovarian cancer","volume":"91","author":"Ness","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2009.01.001_bib27","first-page":"239","article-title":"NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer","volume":"51","author":"Altinoz","year":"2004","journal-title":"Neoplasma"},{"key":"10.1016\/j.maturitas.2009.01.001_bib28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1677\/erc.0.0060093","article-title":"The role of cytokines in both the normal and malignant ovary","volume":"6","author":"Nash","year":"1999","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.maturitas.2009.01.001_bib29","first-page":"12","article-title":"Molecular pathology of epithelial ovarian cancer","author":"Christie","year":"2006","journal-title":"J Br Menopause Soc"},{"key":"10.1016\/j.maturitas.2009.01.001_bib30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L","article-title":"Cancer risk in mutation carriers of DNA-mismatch-repair genes","volume":"81","author":"Aarnio","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.maturitas.2009.01.001_bib31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/gyno.2001.6279","article-title":"The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer","volume":"82","author":"Watson","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ygyno.2005.08.035","article-title":"Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival","volume":"100","author":"Beeghly","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib33","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1158\/1055-9965.EPI-07-0542","article-title":"Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set","volume":"16","author":"Beesley","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.maturitas.2009.01.001_bib34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/sj.bjc.6604170","article-title":"Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis","volume":"98","author":"Pearce","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.maturitas.2009.01.001_bib35","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0090-8258(03)00264-6","article-title":"Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma","volume":"90","author":"Gemignani","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2009.01.001_bib37","first-page":"1344","article-title":"Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas","volume":"58","author":"Palacios","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.maturitas.2009.01.001_bib38","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1517\/14728222.12.9.1139","article-title":"Akt as a therapeutic target in cancer","volume":"12","author":"Steelman","year":"2008","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.maturitas.2009.01.001_bib39","doi-asserted-by":"crossref","first-page":"7678","DOI":"10.1158\/0008-5472.CAN-04-2933","article-title":"Mutation of the PIK3CA gene in ovarian and breast cancer","volume":"64","author":"Campbell","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.maturitas.2009.01.001_bib40","first-page":"2095","article-title":"Frequent PTEN\/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors","volume":"58","author":"Obata","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.maturitas.2009.01.001_bib41","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/cncr.23601","article-title":"A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer","volume":"113","author":"Pal","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2009.01.001_bib42","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1002\/1097-0142(20011201)92:11<2829::AID-CNCR10094>3.0.CO;2-3","article-title":"Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors","volume":"92","author":"Gras","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2009.01.001_bib43","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(98)10261-1","article-title":"Screening for ovarian cancer: a pilot randomised controlled trial","volume":"353","author":"Jacobs","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2009.01.001_bib44","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nature06917","article-title":"Imaging in the era of molecular oncology","volume":"452","author":"Weissleder","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.maturitas.2009.01.001_bib45","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s00428-006-0189-2","article-title":"Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review","volume":"448","author":"Dietel","year":"2006","journal-title":"Virchows Arch"},{"key":"10.1016\/j.maturitas.2009.01.001_bib46","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2007.14.4378","article-title":"Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation","volume":"26","author":"Varadhachary","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib47","unstructured":"http:\/\/www.cancer.gov\/clinicaltrials\/GOG-0239. (Accessed 15\/12\/08)."},{"key":"10.1016\/j.maturitas.2009.01.001_bib48","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/sj.bjc.6604783","article-title":"KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer","volume":"99","author":"Nakayama","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.maturitas.2009.01.001_bib49","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1080\/01635580802100851","article-title":"Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids","volume":"60","author":"Luo","year":"2008","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.maturitas.2009.01.001_bib50","unstructured":"http:\/\/www.cancer.gov\/clinicaltrials\/GOG-0170I. (Accessed 15\/12\/08)."},{"key":"10.1016\/j.maturitas.2009.01.001_bib51","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3892\/ijo_32_6_1145","article-title":"The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)","volume":"32","author":"Oei","year":"2008","journal-title":"Int J Oncol"},{"key":"10.1016\/j.maturitas.2009.01.001_bib52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1196\/annals.1414.020","article-title":"The potential of PARP inhibitors in genetic breast and ovarian cancers","volume":"1138","author":"Drew","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.maturitas.2009.01.001_bib53","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.maturitas.2009.01.001_bib54","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.maturitas.2009.01.001_bib55","doi-asserted-by":"crossref","unstructured":"P. C. Fong, D. S. Boss, C. P. Carden, et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. J Clin Oncol, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 5510.","DOI":"10.1200\/jco.2008.26.15_suppl.5510"},{"key":"10.1016\/j.maturitas.2009.01.001_bib56","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00516373. (Accessed 15\/12\/08)."},{"key":"10.1016\/j.maturitas.2009.01.001_bib57","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00753545. (Accessed 15\/12\/08)."},{"key":"10.1016\/j.maturitas.2009.01.001_bib58","unstructured":"http:\/\/www.cancer.gov\/clinicaltrials\/CRUK-PH2\/052. (Accessed 15\/12\/08)."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512209000024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512209000024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:46:18Z","timestamp":1759913178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512209000024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0378512209000024"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2009.01.001","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diverse molecular pathways in ovarian cancer and their clinical significance","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2009.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}